Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590390 | 1.00 | CCR3 (0.43) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL10262 | 0.83 | CCR3 (0.46) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL9967 | 0.81 | CCR3 (0.44) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL4735 | 0.81 | CCR3 (0.44) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL12701761 | 0.81 | CCR3 (0.44) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL10839 | 0.80 | CCR3 (0.42) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL10840 | 0.80 | CCR3 (0.42) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL1590437 | 0.79 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL1590766 | 0.78 | CCR3 (0.41) | CCR3OPRM1OPRL1EGLN1SIGMAR1 | |
| SCHEMBL1590764 | 0.78 | CCR3 (0.41) | CCR3OPRM1OPRL1EGLN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | CCR3 2793/4885OPRM1 4101/4885OPRL1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.